title: Administration of Brincidofovir and Convalescent Plasma in a Patient With Ebola Virus Disease.
abstract: From 2014 to May 2015, >26 000 Ebola virus disease (EVD) cases were reported from West Africa. We present a patient with EVD who received brincidofovir and convalescent plasma. The relative contributions of supportive care, investigational therapies, and patient's immune-response on survival could not be determined. Randomized trials are needed.
authors.affiliation: Infectious Diseases Division Transplant Surgery Program, University of Nebraska Medical Center, Omaha.
authors.forename: Diana F
authors.initials: DF
authors.lastname: Florescu
authors.affiliation: Infectious Diseases Division.
authors.forename: Andre C
authors.initials: AC
authors.lastname: Kalil
authors.affiliation: Infectious Diseases Division.
authors.forename: Angela L
authors.initials: AL
authors.lastname: Hewlett
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology National Center for Emerging and Zoonotic.
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Schuh
authors.affiliation: Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology National Center for Emerging and Zoonotic.
authors.forename: Ute
authors.initials: U
authors.lastname: Stroher
authors.affiliation: Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Uyeki
authors.affiliation: Infectious Diseases Division.
authors.forename: Philip W
authors.initials: PW
authors.lastname: Smith
mesh_terms: D000328:Adult; D000354:Africa, Western; D000410:Alanine Transaminase / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D019142:Hemorrhagic Fever, Ebola / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage*; D010949:Plasma; D010976:Platelet Count; D012367:RNA, Viral / Q000097:blood; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D063065:Organophosphonates; D012367:RNA, Viral; C525733:brincidofovir; D003596:Cytosine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin
keywords: Ebola; investigational therapies; trials